Agoura Hills, United States
Oncotelic, headquartered in the United States, is an innovative player in the Health and Wellness and Pharmaceutical industries. Established in 1988, the company focuses on developing immunotherapeutics using AI-driven technology to combat cancer, COVID-19, and other viral infections. Their slogan, "AI driven developer of immunotherapeutics against cancer and covid-19 and other viruses," reflects their mission and technological approach.
At the core of Oncotelic is the integration of PointR AI clustercomputing, the Oncotelic antisense platform, and Mateon vascular disrupting agent. Their lead asset, OT-101, targets TGF-beta pathways and has applications in both oncology and virology, presenting a dual market opportunity.
While the company has not disclosed details of recent investments or backers, its longstanding presence and innovative pipeline position it as a compelling prospect for venture capital interest in the biotech sector.
